Skip to main content

Table 4 Treatment factors and results of the TA groups

From: Can metagenomic next-generation sequencing identify the pathogens responsible for culture-negative prosthetic joint infection?

CaseTsukayama typeSurgical protocolmNGS resultsIntravenous antibiotic regimenOral antibiotic regimenReason for culture-negative resultFollow-up (month)Subsequent interventionAntibiotic costs (Yuan)
InitialTargeted
TA-1IVTwo-stage revisionStaphylococcus aureusVancomycin
Meropenem
VancomycinLevofloxacin
Rifampicin
Prior use of antibiotics2411,146.6
TA-2IVTwo-stage revisionParvimonas micraVancomycin
Imipenem
Amoxicillin
Clavulanate
Amoxicillin/ClavulanateFastidious bacteria2310,421
TA-3IVTwo-stage revisionCorynebacteriumVancomycin
Meropenem
VancomycinLevofloxacin
Rifampicin
Prior use of antibiotics3216,661.04
TA-4IVTwo-stage revisionStaphylococcus epidermidisVancomycin
Ceftazidime
VancomycinLinezolidPrior use of antibiotics3010,312.27
TA-5III&DMycoplasma hominisVancomycin
Meropenem
LevofloxacinDoxycycline LevofloxacinFastidious bacteria188391.27
TA-6III&DMycoplasma hominisVancomycin
Meropenem
LevofloxacinDoxycycline LevofloxacinFastidious bacteria278391.27
TA-7IIOne-stage revisionStreptococcus agalactiaeVancomycin
Ceftazidime
CeftriaxoneLevofloxacinUnknown1811,946.99
TA-8IVI&DStaphylococcus epidermidisVancomycin LevofloxacinVancomycinMoxifloxacin
Rifampicin
Unknown2711,016.02
TA-9IVI&DMycoplasma hominisVancomycin CeftazidimeLevofloxacinLevofloxacin DoxycyclineUnknown272959.54
TA-10IVI&DStaphylococcus epidermidisVancomycin TazocinVancomycinLinezolidUnknown199298.5
TA-11IVTwo-stage revisionFinegoldia magnaVancomycin
Meropenem
Vancomycin TazocinAmoxicillin
Clavulanate
Fastidious bacteria1715,499.49
TA-12IVTwo-stage revisionCandida tropicalisVancomycinFluconazoleFluconazoleFastidious bacteria125925.74